Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
22 Junio 2023 - 6:12AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of: June 2023 (Report No. 2)
Commission File Number: 001-38428
PolyPid Ltd.
(Translation of registrant’s name into
English)
18 Hasivim Street
Petach Tikva 495376, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
CONTENTS
Attached hereto and incorporated herein is PolyPid
Ltd.’s (the “Registrant”) press release issued on June 22, 2023, titled “PolyPid Announces Recruitment of First
Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site
Infections.”
The first two paragraphs and
the section titled “Forward-looking Statements” in the press release are incorporated
by reference into the Registrant’s registration statements on Form F-3 (File No. 333-257651) and Form S-8 (File No. 333-239517
and File No. 333-271060), filed with the Securities and Exchange Commission, to be a part
thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
POLYPID LTD. |
| |
|
|
| Date: June 22, 2023 |
By: |
/s/ Dikla Czaczkes Akselbrad |
| |
|
Name: |
Dikla Czaczkes Akselbrad |
| |
|
Title: |
Chief Executive Officer |
3
PolyPid (NASDAQ:PYPD)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
PolyPid (NASDAQ:PYPD)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
